Top-News
Biotechnologie USA

Grace Therapeutics Inc Aktie

Aktie
WKN:  A40LEL ISIN:  US00439U1043 US-Symbol:  GRCE
3,06 $
+0,35 $
+12,92%
2,7066 € 20:43:16 Uhr
Depot/Watchlist
Aktienanzahl *
10,14 Mio.
Marktkapitalisierung *
22,55 Mio. €
Streubesitz
41,02%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 06.11.2024

Grace Therapeutics Inc News

10.07.23 - PR Newswire
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients PR Newswire
07.07.23 - PR Newswire
Acasti Pharma Announces 1-for-6 Reverse Stock Split
Acasti Pharma Announces 1-for-6 Reverse Stock Split PR Newswire
05.07.23 - PR Newswire
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023
Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 PR ...
23.06.23 - PR Newswire
Acasti Pharma Reports Fiscal Year 2023 Operational Results
Acasti Pharma Reports Fiscal Year 2023 Operational Results PR Newswire
22.06.23 - PR Newswire
Acasti Announces Appointment of New Scientific Advisory Board Members
Acasti Announces Appointment of New Scientific Advisory Board Members PR Newswire
08.05.23 - PR Newswire
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through ...
04.04.23 - PR Newswire
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND
Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND PR Newswire
04.04.23 - PR Newswire
Acasti Announces Appointment of Prashant Kohli as CEO
Acasti Announces Appointment of Prashant Kohli as CEO PR Newswire
30.03.23 - PR Newswire
Acasti Pharma Inc. Announces the Resignation of a Director
Acasti Pharma Inc. Announces the Resignation of a Director PR Newswire
13.03.23 - PR Newswire
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange PR Newswire
08.03.23 - PR Newswire
Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference
Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference PR Newswire
28.02.23 - PR Newswire
Acasti Pharma Recognizes Rare Disease Day
Acasti Pharma Recognizes Rare Disease Day PR Newswire
07.02.23 - PR Newswire
Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023
Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 PR Newswire
28.12.22 - PR Newswire
Thinking about buying stock in Minerva Surgical, IQIYI, Cosmos Health, Acasti Pharma, or AMC Entertainment?
Thinking about buying stock in Minerva Surgical, IQIYI, Cosmos Health, Acasti Pharma, or AMC Entertainment? PR Newswire
22.12.22 - PR Newswire
Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma?
Thinking about buying stock in Thermogenesis Holdings, ProQR Therapeutics, Grom Social, ORIC Pharmaceuticals, or Acasti Pharma? PR Newswire
23.05.22 - PR Newswire
Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program PR Newswire
23.12.21 - PR Newswire
Thinking about buying stock in SeaChange International, American Virtual Cloud Technologies, Quoin Pharmaceuticals, Acasti Pharma, or CohBar?
Thinking about buying stock in SeaChange International, American Virtual Cloud Technologies, Quoin Pharmaceuticals, Acasti Pharma, or CohBar? PR Newswire
22.12.21 - PR Newswire
Thinking about buying stock in Naked Brand, Biondvax Pharmaceuticals, eMagin Corp, Red Cat, or Acasti Pharma?
Thinking about buying stock in Naked Brand, Biondvax Pharmaceuticals, eMagin Corp, Red Cat, or Acasti Pharma? PR Newswire
27.08.21 - PR Newswire
Thinking about buying stock in Support.com, Neurometrix, Exela Technologies, Takung Art, or Acasti Pharma?
Thinking about buying stock in Support.com, Neurometrix, Exela Technologies, Takung Art, or Acasti Pharma? PR Newswire
03.07.21 - PR Newswire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acasti Pharma, Inc. - ACST
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acasti Pharma, Inc. - ACST PR Newswire

Newssuche

Videos

newspaper
30.04.25 +22,47%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »